Trials / Withdrawn
WithdrawnNCT03193346
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin Type A | Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas. |
| DRUG | placebo (sodium chloride 0.9 mg) | Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas. |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2021-03-25
- Completion
- 2021-03-25
- First posted
- 2017-06-20
- Last updated
- 2017-07-14
Source: ClinicalTrials.gov record NCT03193346. Inclusion in this directory is not an endorsement.